The Latin America, Middle East and Africa Insomnia Market would witness market growth of 9.8% CAGR during the forecast period (2022-2028).
Numerous physical and mental health conditions and insomnia are related to one another. Consistent sleep deprivation raises therisk for diseases like high blood pressure, heart disease, diabetes, and chronic pain. In addition to prescription medicines, over-the-counter medicines can also cause insomnia. Consulting thedoctor for advice on how to treat thecondition or medication, as well as thesleep issues, if it has been proven that it causes insomnia is crucial. Without treatment, insomnia is not likely to get better.
Many adults eventually go through short-term or acute insomnia, which can last for days or weeks. Typically, stress or a traumatic event is the cause. However, some people experience chronic long-term sleep disorder that lasts for a month or even longer. The main issue might be insomnia, or it might also be related to other illnesses or medications. To find out the cause of the sleep disorder & how to treat it, consulting a doctor is essential.
The average amount of sleep time for study participants was 5 hours and 24 minutes, which is significantly less than the amount of time suggested by sleep standards. The study's findings also revealed a strong correlation between total sleep time & overall sleep quality with excitement. Future research should concentrate on methods to enhance the quality of sleep and elements that influence the effectiveness of sleep. The insomnia market is expanding in this region due to the rising incidence of insomnia among students.
The Brazil market dominated the LAMEA Insomnia Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $126.4 million by 2028. The Argentina market is exhibiting a CAGR of 10.4% during (2022-2028). Additionally, The UAE market would showcase a CAGR of 9.5% during (2022-2028).
Based on Distribution Channel, the market is segmented into Hospital, Retail, and Others. Based on Therapy Type, the market is segmented into Pharmacological and Non-Pharmacological.Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Currax Pharmaceuticals LLC (Currax Holdings USA LLC), Eisai Co., Ltd., Merck Group, Pfizer, Inc., Vanda Pharmaceuticals, Inc., Cadila Healthcare Ltd. (Zydus Cadila), Sanofi S.A., Viatris, Inc., Takeda Pharmaceutical Company Limited, and Purdue Pharma L.P.
Numerous physical and mental health conditions and insomnia are related to one another. Consistent sleep deprivation raises therisk for diseases like high blood pressure, heart disease, diabetes, and chronic pain. In addition to prescription medicines, over-the-counter medicines can also cause insomnia. Consulting thedoctor for advice on how to treat thecondition or medication, as well as thesleep issues, if it has been proven that it causes insomnia is crucial. Without treatment, insomnia is not likely to get better.
Many adults eventually go through short-term or acute insomnia, which can last for days or weeks. Typically, stress or a traumatic event is the cause. However, some people experience chronic long-term sleep disorder that lasts for a month or even longer. The main issue might be insomnia, or it might also be related to other illnesses or medications. To find out the cause of the sleep disorder & how to treat it, consulting a doctor is essential.
The average amount of sleep time for study participants was 5 hours and 24 minutes, which is significantly less than the amount of time suggested by sleep standards. The study's findings also revealed a strong correlation between total sleep time & overall sleep quality with excitement. Future research should concentrate on methods to enhance the quality of sleep and elements that influence the effectiveness of sleep. The insomnia market is expanding in this region due to the rising incidence of insomnia among students.
The Brazil market dominated the LAMEA Insomnia Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $126.4 million by 2028. The Argentina market is exhibiting a CAGR of 10.4% during (2022-2028). Additionally, The UAE market would showcase a CAGR of 9.5% during (2022-2028).
Based on Distribution Channel, the market is segmented into Hospital, Retail, and Others. Based on Therapy Type, the market is segmented into Pharmacological and Non-Pharmacological.Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Currax Pharmaceuticals LLC (Currax Holdings USA LLC), Eisai Co., Ltd., Merck Group, Pfizer, Inc., Vanda Pharmaceuticals, Inc., Cadila Healthcare Ltd. (Zydus Cadila), Sanofi S.A., Viatris, Inc., Takeda Pharmaceutical Company Limited, and Purdue Pharma L.P.
Scope of the Study
Market Segments Covered in the Report:
By Distribution Channel
- Hospital
- Retail
- Others
By Therapy Type
- Pharmacological
- Non-Pharmacological
By Country
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- Currax Pharmaceuticals LLC (Currax Holdings USA LLC)
- Eisai Co., Ltd.
- Merck Group
- Pfizer, Inc.
- Vanda Pharmaceuticals, Inc.
- Cadila Healthcare Ltd. (Zydus Cadila)
- Sanofi S.A.
- Viatris, Inc.
- Takeda Pharmaceutical Company Limited
- Purdue Pharma L.P.
Unique Offerings from the Publisher
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 4. LAMEA Insomnia Market by Distribution Channel
Chapter 5. LAMEA Insomnia Market by Therapy Type
Chapter 6. LAMEA Insomnia Market by Country
Chapter 7. Company Profiles
Companies Mentioned
- Currax Pharmaceuticals LLC (Currax Holdings USA LLC)
- Eisai Co., Ltd.
- Merck Group
- Pfizer, Inc.
- Vanda Pharmaceuticals, Inc.
- Cadila Healthcare Ltd. (Zydus Cadila)
- Sanofi S.A.
- Viatris, Inc.
- Takeda Pharmaceutical Company Limited
- Purdue Pharma L.P.
Methodology
LOADING...
